Cellens Inc
Cellens is commercializing an AI-based, cell-imaging platform for bladder cancer diagnostics. The platform leverages atomic force microscopy (AFM) imaging and machine learning modeling to perform a non-invasive test that quantifies physio-biomarkers on cell surfaces. By analyzing urine samples they can provide a diagno
Cellens Inc is a company in computational bio based in Cambridge, MASSACHUSETTS, founded in 2021.
Profile
Cellens is developing and commercializing a non-invasive urine-based test for cancer-monitoring purposes. Cellens has pioneered label-free cell analysis with a combination of high-resolution nanoscale imaging and proprietary machine learning. Our novel application of quantitative physical properties analysis in cancer cell detection reveals new clinically meaningful information – and high-performing diagnostic tests.
As a business in computational bio, Cellens Inc is listed here with the public details available about it.
Its base of operations is Cambridge, MASSACHUSETTS.
It is recorded at the Regulation D stage.
Its team size is recorded as 2-10 employees.
Total disclosed funding stands at about $1M.
| Sector | Computational Bio |
|---|---|
| Headquarters | Cambridge, MASSACHUSETTS |
| Country | United States |
| Founded | 2021 |
| Employees | 2-10 |
| Stage | Regulation D |
| Total funding | $1,000,000 |
Website: cellensinc.com
Browse related
Create a free account